A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

November 6, 2026 updated by: Zenas BioPharma (USA), LLC

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

The study consists of the following periods:

  • Screening Period: Up to 4 weeks.
  • Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
  • Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
  • Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
  • Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).

All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.

Study Type

Interventional

Enrollment (Estimated)

990

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • New South Wales
      • Kogarah, New South Wales, Australia, 2217
        • Recruiting
        • Southern Neurology Suite 2
      • Sovet, Belgium, 1408
        • Recruiting
        • DCC Neoclinic - Sofia
    • Limburg
      • Overpelt, Limburg, Belgium, 3900
        • Recruiting
        • MS-Netwerk Limburg - Revalidatie
      • Pleven, Bulgaria, 5800
        • Recruiting
        • Avis Medica Hospital Pleven
    • Plovdiv
      • Plovdiv, Plovdiv, Bulgaria, 4000
        • Recruiting
        • Medical Center Nevrocentrum
    • Sofia
      • Sofia, Sofia, Bulgaria, 1680
        • Recruiting
        • Diagnostic and Consultative Center Convex
      • Sofia, Sofia, Bulgaria, 1510
        • Recruiting
        • Medical Center Hera EOOD
    • Tarnovo
      • Veliko Tarnovo, Tarnovo, Bulgaria, 5000
        • Recruiting
        • Medical Center Medica Plus OOD
      • Zagreb, Croatia, 10 000
        • Recruiting
        • Klinicki Bolnicki Centar Zagreb-Rebro
      • Choceň, Czechia, 56501
        • Recruiting
        • NEUROHK, s.r.o.
      • Jihlava, Czechia, 58601
        • Recruiting
        • Regional Hospital Jihlava
    • Harju
      • Tallinn, Harju, Estonia, 10617
        • Recruiting
        • Astra clinic (Clinic4U)
    • Brest
      • Pordic, Brest, France, 29609
        • Recruiting
        • CHU Brest Hospital Cavale
    • Gard
      • Nîmes, Gard, France, 30029
        • Recruiting
        • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
    • Yveline
      • Poissy, Yveline, France, 78300
        • Recruiting
        • Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
      • Tbilisi, Georgia, 0114
        • Recruiting
        • LTD Pineo Medical Ecosystem
      • Tbilisi, Georgia, 0186
        • Recruiting
        • Raymann, LLC
      • Tbilisi, Georgia, 0159
        • Recruiting
        • NNLE Jo Ann University Hospital
      • Tbilisi, Georgia, 0186
        • Recruiting
        • Caucasus Medical Center Ltd
    • K'alak'i T'bilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 0114
        • Recruiting
        • JSC Curatio
    • Saburtalo
      • Tbilisi, Saburtalo, Georgia, 0160
        • Recruiting
        • MD Georgia Staff Physician MediClub Georgia
    • Hesse
      • Bad Homburg, Hesse, Germany, 61348
        • Recruiting
        • Zentrum fur klinische Forschung Dr.Scholl GmbH
    • Athens
      • Cholargós, Athens, Greece, 15562
        • Recruiting
        • Metropolitan General Hospital
    • Attica
      • Athens, Attica, Greece, 11526
        • Recruiting
        • Errikos Dunant Hospital
      • Budapest, Hungary, 1145
        • Recruiting
        • National Institute of Clinical Neurosciences
      • Tatabánya, Hungary, 2800
        • Recruiting
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Komarom-Esztergom Vamegye
      • Esztergom, Komarom-Esztergom Vamegye, Hungary, 2500
        • Recruiting
        • Valeomed Kft.
    • Chieti
      • Chieti, Chieti, Italy, 66100
        • Recruiting
        • University G. D'Annunzio of Chieti-Pescara
    • Isernia/Molise
      • Pozzilli, Isernia/Molise, Italy, 86077
        • Recruiting
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
    • Kauno
      • Kaunas, Kauno, Lithuania, 50161
        • Recruiting
        • Hospital of Lithuanian University of Health Sciences
      • Lublin, Poland, 20-064
        • Recruiting
        • Galen Clinic
      • Plewiska, Poland, 62-064
        • Recruiting
        • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
      • Poznan, Poland, 15-540
        • Recruiting
        • Prywatna Lecznica Certus Sp. z o.o.
      • Szczecin, Poland, 70-111
        • Recruiting
        • EUROMEDIS Osrodek Badan Klinicznych
      • Żory, Poland, 44-240
        • Recruiting
        • Centrum Medyczne ProNeuro Żory
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland, 85-605
        • Recruiting
        • Centrum Medyczne INTERCOR Sp. z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Poland, 20-601
        • Recruiting
        • Malva Trials
      • Lublin, Lublin Voivodeship, Poland, 20-064
        • Recruiting
        • Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
      • Lublin, Lublin Voivodeship, Poland, 20-064
        • Recruiting
        • NZOZ Neuromed M. i M. Nastaj Sp.P
    • Lubusz Voivodeship
      • Nowa Sól, Lubusz Voivodeship, Poland, 67-100
        • Recruiting
        • Twoja Przychodnia Centrum Medyczne Nowa Sól
    • Mazovian
      • Warsaw, Mazovian, Poland, 02-172
        • Recruiting
        • MTZ Clinical Researcz Powered by pratia
    • Rzeszów
      • Rzeszów, Rzeszów, Poland, 35-323
        • Recruiting
        • Nmedis sp. z o.o.
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Poland, 40-081
        • Recruiting
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, Poland, 40-571
        • Recruiting
        • MA-LEK Clinical Sp. z o.o.
      • Katowice, Silesian Voivodeship, Poland, 40-584
        • Recruiting
        • NZOZ Novo Med
    • Upper Silesia
      • Katowice, Upper Silesia, Poland, 40-686
        • Recruiting
        • Neuro Medic Clinic
    • Wielkopolska
      • Poznan, Wielkopolska, Poland, 61-853
        • Recruiting
        • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
      • Poznan, Wielkopolska, Poland, 60-324
        • Recruiting
        • Twoja Przychodnia PCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Poland, 91-743
        • Recruiting
        • PRO SALUS Sp. z o.o. sp.k.
      • Lodz, Łódź Voivodeship, Poland, 90-324
        • Recruiting
        • Centrum Neurologii Krzysztof Selmaj
      • Guaynabo, Puerto Rico, 00969
        • Recruiting
        • Caribbean Center for Clinical Research
    • Constanța County
      • Constanța, Constanța County, Romania, 900123
        • Recruiting
        • Spital Clinic CF Constanta
    • Suceava
      • Radauti, Suceava, Romania, 725400
        • Recruiting
        • Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
      • Kragujevac, Serbia, 34000
        • Recruiting
        • University Clinical Centre of Kragujevac
      • Niš, Serbia, 18000
        • Recruiting
        • Clinic of Neurology - Clinical Center Nis
    • Belgrade
      • Belgrade, Belgrade, Serbia, 11000
        • Recruiting
        • University Clinical Centre of Serbia
    • A Coruña
      • A Coruña, A Coruña, Spain, 15006
        • Recruiting
        • Complejo Hospitalario Universitario A Coruña
    • Galicia
      • Vigo, Galicia, Spain, 36312
        • Recruiting
        • Hospital Alvaro Cunqueiro
    • Madrid
      • Madrid, Madrid, Spain, 28007
        • Recruiting
        • Hospital Gregorio Marañon
      • Majadahonda, Madrid, Spain, 28222
        • Recruiting
        • Hospital Universitario Puerta de Hierro de Majadahonda
    • Málaga
      • Málaga, Málaga, Spain, 29016
        • Recruiting
        • Vithas Hospital Parque San Antonio
    • Seville
      • Castilleja de la Cuesta, Seville, Spain, 41950
        • Recruiting
        • Hospital Vithas Nisa Sevilla
      • Ivano-Frankivsk, Ukraine, 76943
        • Recruiting
        • Neuro Global
      • Lviv, Ukraine, 79010
        • Recruiting
        • Lviv National Medical University named after Danylo Galytskiy
      • Vinnytsia, Ukraine, 21009
        • Recruiting
        • Medical Clinical Investigational Center of Medical Center LLC Health Clinic
    • Chernivtsi Oblast
      • Chernivtsi, Chernivtsi Oblast, Ukraine, 58023
        • Recruiting
        • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
    • Ivano-Frankivs'k Oblast
      • Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraine, 76018
        • Recruiting
        • CNE City Clinical Hospital #1 of Ivano-Frankivsk council
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79000
        • Recruiting
        • Limited Liability Company Medical Center Neuroclinic
      • Lviv, Lviv Oblast, Ukraine, 79029
        • Recruiting
        • Limited Liability Company "Neurofocus"
    • Arizona
      • Phoenix, Arizona, United States, 85032
        • Recruiting
        • Arizona Neuroscience Research, LLC
      • Scottsdale, Arizona, United States, 85253
        • Recruiting
        • Perseverance Research Center, LLC (PRC)
    • California
      • Fullerton, California, United States, 92835
        • Recruiting
        • Fullerton Neurology and Headache Center
      • Torrance, California, United States, 90502-2006
        • Recruiting
        • Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
      • West Hollywood, California, United States, 90048
        • Recruiting
        • Regina Berkovich MD, PhD Inc
    • Florida
      • Boca Raton, Florida, United States, 33487
        • Recruiting
        • SFM Clinical Research, LLC
      • Bradenton, Florida, United States, 34209
        • Recruiting
        • Nova Clinical Research, LLC
      • Clearwater, Florida, United States, 33761
        • Recruiting
        • MS and Neuromuscular Center of Excellence
      • Maitland, Florida, United States, 32751
        • Recruiting
        • Neurology Associates
      • Naples, Florida, United States, 34105
        • Recruiting
        • Aqualane Clinical Research
      • Tampa, Florida, United States, 33612
        • Recruiting
        • University of South Florida Department of Neurology - MS Division
    • Indiana
      • Indianapolis, Indiana, United States, 46256
        • Recruiting
        • Josephson Wallack Munshower Neurology, Pc Suite 225
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Recruiting
        • University of Kansas Medical Center
      • Roeland Park, Kansas, United States, 66205
        • Recruiting
        • KC Research Center, PA Neurology Research Dept
    • Massachusetts
      • Boston, Massachusetts, United States, 02131
        • Withdrawn
        • Boston Clinical Trials
      • Worcester, Massachusetts, United States, 01655
        • Recruiting
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Rochester Hills, Michigan, United States, 48307
        • Recruiting
        • Profound Research LLC at Oakland Neurology Center
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • Recruiting
        • University Of New Mexico School Of Medicine
    • New York
      • New York, New York, United States, 10029
        • Recruiting
        • Mount Sinai Medical Center
    • Ohio
      • Columbus, Ohio, United States, 43235
        • Recruiting
        • The Boster Center for Multiple Sclerosis
      • Columbus, Ohio, United States, 43221
        • Recruiting
        • The Ohio State University Wexner Medical Center (OSUWMC)
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Recruiting
        • OMRF Multiple Sclerosis Center of Excellence
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Recruiting
        • Premier Neurology
    • Tennessee
      • Cordova, Tennessee, United States, 38018
        • Recruiting
        • Neurology Clinic, P.C.
    • Texas
      • San Antonio, Texas, United States, 78258
        • Recruiting
        • Lone Star Neurology
      • Sherman, Texas, United States, 75092
        • Recruiting
        • Texas Institute for Neurological Disorders - Sherman

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
  3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
  4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
  5. Absence of clinical relapses for at least 24 months.

Exclusion Criteria:

  1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
  2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
  3. History or current diagnosis of other neurological disorders that may mimic MS
  4. History or current diagnosis of progressive multifocal leukoencephalopathy
  5. Active, clinically significant viral, bacterial, or fungal infection
  6. History of any other significant active medical condition
  7. History of suicidal behavior within 6 months prior to Screening
  8. Any prior history of malignancy
  9. Patients on anticoagulation, or antiplatelet therapy
  10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
  11. Clinically significant laboratory abnormalities at Screening.
  12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
  13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Orelabrutinib Group

Orelabrutinib PO daily

Orelabrutinib orally

Placebo Comparator: Placebo Group

Placebo PO daily

Placebo orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Time Frame: Up to approximately 120 weeks

Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0

Up to approximately 120 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
12 Week CDP
Time Frame: Up to approximately 120 weeks

Time to onset of CDP events on EDSS, confirmed over at least 12 weeks

Up to approximately 120 weeks
T2 lesions on MRI
Time Frame: Up to approximately 120 weeks

The total number of new or enlarging T2 lesions on MRI scans of the brain

Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Time Frame: Up to approximately 120 weeks

Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDP-T25FWT
Time Frame: Up to approximately 120 weeks

Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI
Time Frame: Up to approximately 120 weeks

Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-9HPT
Time Frame: Up to approximately 120 weeks

Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-T25FWT
Time Frame: Up to approximately 120 weeks

Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
Symbol Digit Modalities Test
Time Frame: Up to approximately 120 weeks

The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit

Up to approximately 120 weeks
Annualized relapse rate
Time Frame: Up to approximately 120 weeks

Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses

Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Time Frame: Up to approximately 120 weeks

Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);

Up to approximately 120 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 23, 2026

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

July 1, 2030

Study Registration Dates

First Submitted

December 18, 2025

First Submitted That Met QC Criteria

December 19, 2025

First Posted (Actual)

December 23, 2025

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ZB020-03-002

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.